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ABSTRACT
Age-related macular degeneration (AMD) is a disease of the retina that not only affects the visual 
function, but also influences the patient’s general health and quality of life. For this reason, visual 
health assessment, which typically uses clinical indicators, should also include an evaluation that 
would allow to get a numerical value that represents the disease within the functional state of 
the patient. Objective: To establish statistically significant differences in health-related quality of 
life (HRQL) in participants diagnosed with AMD and in healthy patients. Methodology: Cross-
sectional observational analytical study based on a sample of a total of 17 healthy participants and 
13 participants with AMD for pilot tests. A specialist performed a retinal assessment and applied 
the HRQL questionnaire called the National Eye Institute Visual Functioning Questionnaire 
(NEI VFQ-25). Subsequently, a statistical analysis was developed to correlate data from the two 
groups. Results: Differences in HRQL were established among participants with AMD and healthy 
individuals; statistically significant differences (p ≤ 0.05) were found in the following subscales: 
general vision, near activities, distance activity, social functioning, difficulty in a role, visual 
dependency, color vision, and well-being and suffering. Conclusions: Participants with AMD 
presented with a decrease in HRQOL, associated with lower scores on the NEI VFQ-25 subscales.
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INTRODUCTION
Age-Related Macular Degeneration (ARMD) is 
a progressive and chronic ocular condition that 
mostly affects people older than 50 years of age 
(1). It is the main cause of blindness in the west-
ern world for people older than 60 and the third 
most common cause in the world after cataract 
and glaucoma (2). In the study carried out in 
Colombia (3) in a group of 535 people with an 
average age of 67.1 years (55-95 range), the general 
prevalence of ARMD was 4.86%. The prevalence 
of early ARMD was 11.8%. The prevalence of early 
ARMD by age group was: 7.4% (55-59), 9.8% (60-
69), 17.2% (70-79), and 13.6% (older than 80). 
The prevalence of advanced ARMD among the 
different groups is: 0.7% (55-59), 1.0% (60-69), 
8.0% (70-79) and 22.7% (older than 80). ARMD 
is the main cause of loss of central vision, which 
is needed for activities that require detailed vision, 
thus producing alterations when reading, driving 
or recognizing faces, altering color vision, reduc-
ing contrast sensitivity, and metamorphopsias (1). 
With the progressive deterioration of the macula, 
patients with ARMD experience multiple visual 
problems that significantly affect their mental 
health and quality of life (4). It has been document-
ed that patients with conditions that alter visual 
function experience a significant reduction on 
the health-related quality of life (HRQL), which 
is expressed as a greater social dependency, daily 
life difficulties, higher rates of clinical depression, 
higher risk of falling, premature admission to adult 
living facilities, and suicide (4). Because of this, 
the measure of visual health must cover a mental 
and social evaluation of the well-being, which can 
be achieved with the HRQL (5), gaining strength 
as a way to evaluate the population’s health and 
its conditions, since it takes into account the im-
portance of the functional state of the patient 
(including physical, social, and mental state). On 
the other hand, because health care evolves from 
an illness-based model (6) to a patient-centered 
model, the importance of evaluating the results 
of health care from the patient’s perspective is 
now known. Therefore, aside from the clinical 
measures, a number of measuring instruments 
have appeared, allowing patients to express their 
own concepts that evaluate their quality of life, 
their functional state, and their own perception 
experiences (7). Usually, quality of life is measured 
with questionnaires that contain instructions for 
application, and the purpose of those question-
naries is to measure areas or domains such as: pain, 
mobility, and achievement of specific activities, 
among others (6,8,9).
RESUMEN
La degeneración macular asociada con la edad (DMAE) es una enfermedad de la retina 
que no solo afecta la función visual, sino que influye en la salud general del paciente y en 
su calidad de vida; por esta razón, la medición de la salud visual típicamente efectuada 
con los indicadores clínicos debe, además, abarcar una evaluación que permita obtener 
un valor numérico que represente la enfermedad dentro del estado funcional del pacien-
te. Objetivo: establecer diferencias estadísticamente significativas de la calidad de vida 
relacionada con la salud (CVRS) en los participantes diagnosticados con DMAE y en 
pacientes sanos. Metodología: estudio observacional analítico de corte transversal; mues-
tra para pruebas piloto con un total de diecisiete participantes sanos y trece participantes 
con DMAE. Un especialista efectuó una valoración de retina y aplicó el cuestionario de 
CVRS denominado National Eye Institute Visual Functioning Questionnaire (NEI VFQ-
25); posteriormente, se desarrolló un análisis estadístico para correlacionar los datos entre 
los dos grupos. Resultados: se establecieron diferencias en la CVRS entre participantes 
con DMAE e individuos sanos; se encontró en las subescalas visión general, actividades 
de cerca, actividad a distancia, función social, dificultad en un rol, dependencia, visión 
del color y bienestar y sufrimiento diferencias estadísticamente significativas (p ≤ 0,05). 
Conclusiones: los participantes con DMAE presentaron una disminución de la CVRS, 
asociada a puntuaciones más bajas en las subescalas del NEI VFQ-25.
Palabras clave: degenera-
ción macular, calidad de 
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AGE-RELATED MACULAR 
DEGENERATION
ARMD is a degenerative condition of the pho-
toreceptors and the pigment epithelium of the 
retina in human macula. It is characterized by the 
presence of drusens, retinal pigment epithelium 
(RPE) abnormalities, hypo or hyperpigmentation, 
choriocapillaris-RPE geographic atrophy com-
promising or not the center of the fovea and, in 
some occasions, generating choroidal neovascu-
larization (CNV). It is the most common cause 
of visual disability in patients older than 55 years 
in developed countries (10). The ARMD classifi-
cation criteria include the one established by the 
AREDS (Age-Related Eye Disease Study) (11), a 
classification system applied to patients diagnosed 
with ARMD (Table 1).
table 1. Age-Related Macular Degeneration (ARMD) 
classification
ClasifiCation CharaCteristiCs
No ARMD (AREDS 
Category 1)




Combination of multiple small drusen, few 
intermediate drusen (63 to 124 microns of dia-
meter), or RPE abnormalities.
Intermediate ARMD 
(AREDS Category 3)
Extensive intermediate drusen, with at least 
one large drusen (≥125 microns of diameter), 
or geographic atrophy without compromising 
the center of the fovea.
Advanced ARMD 
(AREDS Category 4)
Presence of one or more of the following altera-
tions: RPE-choriocapillaris geographic atrophy 
compromising the center of the fovea, neovascu-
lar maculopathy (choroidal neovascularization, 
RPE or neurosensorial retinal hemorrhagic 
or serous detachment, exudates, sub-retinal 
and sub-RPE fibrovascular proliferation and 
disciform scarring)
Source: AREDS (11).
The main symptoms of macular degeneration 
are: lines and objects distortion, evident visual 
acuity reduction, blurry vision, increasing light 
sensitivity, the sensation of having a permanent 
dark spot in the center of the eye (12). Symptoms 
can be nonspecific in early stages of the dry type 
condition and it can even progress so slowly that 
people are unable to notice any change in their 
vision and, in some cases, particularly when the 
neovascular or wet type is present, the condition 
progresses rapidly and can cause vision loss in 
both eyes (10).
HEALTH-RELATED QUALITY OF LIFE
The demographical and epidemiological chang-
es, the illnesses spreading, and the increased life 
expectancy, have led to a growing interest for 
quality of life and the Health-Related Quality 
of Life (HRQL). According to the World Health 
Organization (WHO) (5), quality of life is the 
result of the perception that people have about 
situations of their everyday life, determined by 
the cultural context in which they live and relat-
ed to the objectives, expectations, regulations, 
and concerns, while the HRQL is the subjective 
perception of well-being, health, and individual 
functionality on different areas of their lives and 
on diverse dimensions of the human being, such 
as the physical, psychological, independence lev-
el, social relations and the relationship with the 
environment (13). The concept of quality of life 
is the social well-being index focused on the life 
situation of an individual regarding their emotional 
development (happiness, satisfaction, ability to 
function in society, normal functioning of their 
social roles and interpersonal relations) trying to 
measure the positive sensation of their life (14).
The HRQL is about a concept that is influenced by 
the physical health of the subject, their psycholog-
ical state, level of independence, social relations, 
and their relationship with the environment. It is 
not only influenced by the nature and magnitude 
of the deterioration, but also by the impact on how 
to function in its environment. Therefore, the 
HRQL evaluation must cover more than the per-
formance of activities, including spiritual well-be-
ing, emotional and social aspects, areas that could 
have been affected by consequence of the illness 
onset. It is a way to study the population’s health 
and conditions, and to analyze the effectiveness 
and efficiency of a treatment or a health system, 
because it takes into account the importance of 
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mental) state of a patient within the multidimen-
sional context in which it takes place, considering 
quality of life as a subjective phenomenon that 
makes it possible to obtain a numeric value that 
represents the condition and state of health of 
the patient (6).
One of the more used instruments in HRQL, 
specifically in visual health, is the National Eye 
Institute Visual Functioning Questionnaire-25 
(NEI VFQ-25), designed to evaluate the impact 
that ocular diseases have on visual functioning 
and the HRQL. The NEI VFQ-25 is the short 
version of the NEI VFQ-51, equally validated 
and reliable, with psychometric properties for 
the ocular conditions. It has been translated into 
nine languages. The NEI VFQ-25 measures the 
everyday life visual function, as well as the social 
and emotional impact of vision opposite to the pa-
tient’s health (15). Mangione et al. (16) developed 
the NEI VFQ-25 questionnaire with the purpose 
of creating a survey that can subjectively measure 
the perception of the visual health state with a 
content of specific conditions for patients with 
age-related ocular chronic diseases. The question-
naire’s questions were designed with the purpose 
of measuring the influence of the visual disability 
and the visual symptoms related to the everyday life 
social and emotional well-being, daily activities and 
visual functioning (17-24). The NEI VFQ-25 is a 
reliable questionnaire, psychometrically valid and 
sensitive to be used on the visual health with the 
purpose of measuring the quality of life of patients 
with different diseases (17). The NEI VFQ-25 is 
a short version of the original 51-items that was 
designed to reduce the load of the original and 
to increase its appropriateness and validity; it was 
planned since the first phase of the long version 
development, despite the success of its results (17).
METHODS
Cross-sectional, analytical and observational study 
of the health-related quality of life of participants 
with ARMD (n = 13) as compared to healthy par-
ticipants (n = 17) according to the methods posed 
by Hertzog (19), in order to calculate the sample 
of the pilot study, which was performed in Bogo-
ta, specifically at the Colombian Ophthalmology 
Center. Each one of the study participants signed 
the informed consent. The study complies with 
the ethical protocols given by the Helsinki dec-
laration for human beings.
In order to conduct the present study, the follow-
ing activities were defined:
1. ARMD diagnosis given by an ophthalmology 
professional with a retina supra-specialty. The 
degree of severity of ARMD was established 
according to the AREDS classification (11).
2. The healthy participants group was equally 
evaluated by a retina supra-specialist to confirm 
the absence of retinal or posterior segment 
conditions.
3. A medical record previously established was 
used for the study, where aspects such as gen-
eral background and visual functional state 
were evaluated.
4. A validated Spanish version of the NEI VFQ-
25 questionnaire was applied.
5. Data analysis.
Participants were selected accordingly to the fol-
lowing criteria:
1. Participants with Age-Related Macular De-
generation:
1.1. Inclusion:
• Females and males between the ages 
of 50 and 90 years old.
• Participants are capable of speaking 
and reading Spanish fluently, without 
any mental or physical disability.
1.2. Exclusion:
• Participants with any illness or con-
dition that affects visual function, 
not due to age-related macular de-
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2. Healthy participants.
2.1. Inclusion:
• Participants with no illness or condi-
tion that affects visual function, capa-
ble of speaking and reading Spanish 
fluently.
• Females and males between the ages 
of 50 and 90 years old.
2.2. Exclusion:
• Participants with any mental retar-
dation or disability.
Fundus examination
The examination was performed by a retina su-
pra-specialist. Each one of the participants was 
examined, establishing the absence of posterior 
segment conditions on the healthy patients and, 
according to characteristics, was classified accord-
ing to the criteria established by the study (11).
Health-related quality of life 
evaluated with the NEI VFQ-25
The previously validated translated version of the 
NEI VFQ-25 was used for this study (25). The 
NEI VFQ-25 consists of 25 questions related to 
visual health, social and emotional well-being and 
visual functioning subscales. This questionnaire 
has been used in patients with ocular conditions 
(17-26) and it contains an item that describes the 
general health of the patient, which has shown to 
be a solid predictor of future health and mortality 
in population-based studies (17).
The questionnaire’s questions are divided into 
eleven scales, where items are grouped according 
to the pre-established classification. The question-
naire includes the following sub-scales: global 
vision rating, difficulty with near vision activities, 
difficulty with distance vision activities, limitations 
in social functioning due to vision, role limitations 
due to vision, dependency on others due to vision, 
well-being and distress, driving difficulties due to 
vision, peripheral vision limitations, ocular pain 
and color vision difficulties (17). According to 
Vargas (20), it takes an average of approximately 
ten minutes to apply the NEI VFQ-25 question-
naire (25).
NEI VFQ-25 score calculation
For the total calculation of the NEI VFQ-25, it 
was necessary to obtain an average of the recoding 
of the subscales, oriented to the visual function 
results. By conducting an average of every subscale 
qualification, the weight of every one of them is 
given (17).
Statistical methods
The statistical data analysis was performed using 
the Graph Pad 6,0 program for Windows. The 
variables were analyzed by descriptive statistical 
methods. The analysis of the quantitative variables 
included mean and standard deviation calcula-
tions. In order to correlate the related variables 
with the questionnaire, the Spearman correlation 
test was performed. A significance level of p ≤ 0.05 
was considered.
RESULTS
A total of 26 eyes with the condition classified as 









figure 1. Percentage distribution of eyes with classified 
condition according to AREDS
Source: Own production.
The final average of each of the healthy partici-
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by grouping each one of the questions on the cor-
respondent subscale (Tables 2 and 3, respectively). 
The maximum score obtained for every subscale 
was 100 points and the minimum was 0. On the 
healthy participants’ results, the subscales with the 
highest average were color vision, dependency, 
social function, and the lowest were ocular pain, 
well-being and distress, and role difficulties. On 
the other hand, the highest average subscales for 
ARMD participants were color vision, peripheral 
vision, and dependency, while the lowest average 
subscales were role difficulties, difficulty with 
near vision activities and global vision rating, re-
spectively.
Differences were established regarding the 
health-related quality of life between ARMD and 
healthy participants, finding a significant statisti-
cal difference of p ≤ 0.05 for the corresponding 
subscales of: global vision rating; difficulty with 
near vision activities; difficulty with distance vision 
activities; social function; role difficulties; depen-
dency; color vision; and well-being and distress. 
No significant statistical differences were found 
in the ocular pain, peripheral vision and driving 
subscales (0.23, 0.14 and 0.22, respectively).
DISCUSSION
It is generally recognized that ARMD is a condi-
tion that not only affects visual function, but also 
the patient’s general health and quality of life, for 
which a measure of the visual health typically eval-
uated with clinical indicators (visual acuity and 
contrast sensitivity) must also cover an evaluation 
that makes it possible to obtain a numeric value 
that represents the condition within the patient’s 
functional state, as well as their physical, mental 
or social state (27).
The NEI VFQ-25 is a questionnaire designed to 
evaluate multiple dimensions of vision related 
to the quality of life, and it has been evaluated 
in diverse populations that also include patients 
with conditions such as ARMD. Some authors 
(4,17,21,22,28,29) have evaluated the internal 
reliability of the NEI VFQ-25 in ARMD patients, 
where all the subscales reliability was over 0.70. 
In this study, each of the 11 sub-scales that eval-
uate the questionnaire was analyzed, obtaining 
table 2. NEI VFQ-25 results in healthy participants, 
showing the highest average on the color vision subscale and 




NEI VFQ-25 Total 17 89.4 ± 8.139
Global vision rating 17 85.6 ± 18.530
Ocular pain 17 72.1 ± 20.506
Near vision activities 17 90.2 ±11.500
Distance vision activities 17 89.7 ± 12.335
Social function 17 97.8 ± 6.607
Role difficulties 17 85.3 ± 18.872
Dependency 17 98.0 ± 6.270
Driving 13 92.3 ±18.069
Color vision 17 100 ± 0.000 
Peripheral vision 17 91.2 ± 15.158
Well-being and distress 17 81.6 ± 12.396
Source: own production.
table 3. NEI VFQ-25 results in ARMD participants, 
showing the highest average on the color vision subscale and 







NEI VFQ-25 Total 13 72.3 ± 10.617 
Global vision rating 13 63.1 ± 13.774
Ocular pain 13 63.5 ± 18.014
Near vision activities 13 60.9 ± 32.522
Distance vision activities 13 64.1 ± 31.802
Social function 13 78.8 ± 29.040
Role difficulties 13 59.6 ± 30.683
Dependency 13 81.4 ± 27.670
Driving 4 81.3 ± 12.500
Color vision 13 90.4 ± 12.659
Peripheral vision 13 80.8 ± 20.801
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significant statistical differences when comparing 
both groups in the study on the following sub-
scales: global vision rating, near vision activities, 
distance vision activities, social function, role dif-
ficulties, dependency, color vision and well-being 
and distress.
In this research, the low scores obtained by the 
ARMD participants, particularly in the sub-scales 
of global vision rating, distance vision activities 
and near vision activities, show the real issues that 
ARMD patients have in accomplishing everyday 
activities that depend on central vision, including 
newspaper reading, good near vision, and the in-
teraction with their environment, specifically at 
home, and the environment where they perform 
their daily activities. The estimates are consistent 
with previous studies on ARMD patients (28,30), 
since those dimensions significantly affect ARMD 
during its natural course. From this study, we 
can determine that, in ARMD patients, the NEI 
VFQ-25 subscales that are more sensitive to visu-
al compromise and to the severity of the disease 
are global vision rating, distance vision activities 
and near vision activities. This may indicate that 
patients with visual compromise have more diffi-
culties to perform most of the daily life activities 
in which vision intervenes.
It is interesting to find that, despite the central 
visual compromise in ARMD participants, they 
showed normal values on color vision, which was 
unexpected. This aspect is related to the fact that 
only one question about picking out clothing dif-
ficulties does not show the real color perception 
limitations that the condition generates; these 
conclusions are similar to those reached by Cahill 
and collaborators in 2003 (26).
The low NEI VFQ-25 scores of ARMD participants 
in social function, role difficulties, dependency, 
well-being and distress sub-scales compared to the 
healthy participants show the isolation effect that 
the condition produces on patients. It is shown 
as a loss of independence, increasing problems 
with social interactions and increase anxiety as a 
result of not being able to adapt to the relatively 
recent visual loss (17,26).
As far as the driving sub-scale is concerned, very 
few of the ARMD participants (23%) still drive, 
compared to healthy participants (76%). No sig-
nificant statistical differences were found between 
the two groups, since the ARMD participants that 
still drive have a minimal visual compromise, 
which is similar to what happened in the study 
by Brody and collaborators (25).
It is particularly note-worthy that ARMD partic-
ipants and healthy ones showed similar average 
values in the ocular pain sub-scale; this possi-
bly happens because this dominion can capture 
symptoms associated to visual fatigue and visual 
demands for prolonged tasks that consequently 
cause great visual strain and discomfort. As far 
as the peripheral vision sub-scale is concerned, 
no significant statistical differences were found 
in either group, possibly due to the little or al-
most null compromise of the peripheral retina 
in ARMD.
CONCLUSIONS
It is established that ARMD participants showed a 
reduced quality of life related to vision associated 
to low scores in the near vision activities, distance 
vision activities, social function, role difficulty, 
dependency, color vision, well-being and distress 
subscales of the NEI VFQ-25.
This study of quality of life in ARMD patients 
shows the profound impact of central vision loss 
and the ability of a person to perform vision-related 
activities. It prevents or restricts the development 
of daily tasks in the patient’s daily life. This re-
search confirms the ability of the NEI VFQ-25 
to capture visual acuity changes and its use on 
ARMD patients, providing evidences that make 
it possible to infer that the questionnaire is a sen-
sitive measure at the time of evaluating quality of 
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This research represents a pilot test to evaluate 
the HRQL in ARMD and healthy patients that 
cannot be extrapolated to the study’s population. 
It reveals limitations regarding the participants’ 
population, since it was selected from a unique 
installation and it has the potential to limit how 
the conclusions are generalized.
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